Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 5/20 | 0.61 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1583361 | 0.83 | MET (0.80) | METPOLBMAPK1SMN1; SMN2RPS6KA3 | |
| SCHEMBL2008858 | 0.78 | MET (0.51) | METJAK2JAK3DHODHSMN1; SMN2 | |
| SCHEMBL4437291 | 0.77 | MET (0.57) | METPOLBMAPK1SMN1; SMN2RPS6KA3 | |
| SCHEMBL2011081 | 0.76 | MET (0.67) | METPOLBMAPK1SMN1; SMN2RPS6KA3 | |
| SCHEMBL4997410 | 0.76 | MET (0.58) | METPOLBMAPK1SMN1; SMN2RPS6KA3 | |
| SCHEMBL1982875 | 0.76 | MET (0.63) | METJAK2POLBMAPK1SMN1; SMN2 | |
| SCHEMBL1583928 | 0.76 | MET (1.00) | METPOLBMAPK1SMN1; SMN2RPS6KA3 | |
| SCHEMBL4437416 | 0.76 | MET (0.60) | METPOLBMAPK1SMN1; SMN2RPS6KA3 | |
| SCHEMBL27780429 | 0.76 | MET (0.57) | METPOLBMAPK1SMN1; SMN2RPS6KA3 | |
| SCHEMBL2013113 | 0.75 | MET (0.63) | METPOLBMAPK1SMN1; SMN2RPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121608-B1 | DIHYDROPYRIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | BAYER IP GMBH (DE) | 2012-11-14 | — | — | EP | claimed |
| WO-2011067189-A2 | CMET INHIBITORS FOR TREATING ENDOMETRIOSIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-06-09 | — | — | WO | claimed |
| EP-2121608-A1 | DIHYDROPYRIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | Bayer Schering Pharma AG (DE) | 2009-11-25 | — | — | EP | claimed |
| CN-101558040-A | Dihydropyridine derivatives useful as protein kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2009-10-14 | — | — | CN | claimed |
| US-20080176833-A1 | DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-07-24 | — | — | US | claimed |
| WO-2008071451-A1 | DIHYDROPYRIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-19 | — | — | WO | claimed |
| EP-2121608-B1 | DIHYDROPYRIDINE DERIVATIVES USEFUL AS PROTEIN KINASE INHIBITORS | BAYER IP GMBH (DE) | 2012-11-14 | — | — | EP | disclosed |
| US-8198456-B2 | e.g. 1,4-dihydro-4-(1H-indazol-5-yl)-2,6-dimethyl-3,5-pyridinedicarbonitrile; c-Met tyrosine kinase inhibitor; antitumor agent; lung, liver, gastric and breast solid tumors; pancreatic cancer, glioma, and hepatocellular carcinoma | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| CN-101558040-A | Dihydropyridine derivatives useful as protein kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2009-10-14 | — | — | CN | disclosed |
| US-20080176833-A1 | DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176833-A1 | DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS | MET, DMPK, RET | MET 1/4885JAK2 169/4885JAK3 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.